Delveinsight

DECEMBER 7, 2020

In May 2020, Freenome initiated AI-EMERGE, a clinical study for the AI-Genomics blood test has been completed, which collected samples from up to 3,000 patients in the US and Canada. The device is worn on the patients’ body, which contains a biharmonic cartridge in it that carries insulin and glucagon.

Protein 56

Protein Insulin Development Hormones 56

Pharmaceutical Technology

MARCH 2, 2023

Keytruda is also indicated as monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy, as well as adults who are not eligible for any platinum-containing chemotherapy.

FDA Approval 100

FDA Approval Containment Development Genome 100

Roots Analysis

SEPTEMBER 9, 2024

The main components of protein expression are a vector (plasmid) containing the gene of interest, and a host cell, for instance mammalian or prokaryotic cell. Hormones (includes recombinant insulin, erythropoietin and growth hormones) Enzyme replacement therapies used in treatment of rare genetic disorders such as Gaucher disease.

Protein 40

Protein Gene Production DNA 40

The Pharma Data

SEPTEMBER 16, 2020

Data will also be presented for two of our investigational hormone receptor (HR)-positive breast cancer treatments, both of which target the PI3K/AKT signalling pathway, a key driver of cancer cell growth and proliferation. GDC-0077 is our next generation investigational PI3K? Presentation #283MO (Oral), Friday, 18 September (On-demand).

HR 52

HR Medicine Hormones Trials 52

The Pharma Data

MARCH 11, 2021

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. Thyroiditis can present with or without endocrinopathy.

Trials 52

Trials Hormones Genome Genomics 52

The Pharma Data

JULY 23, 2021

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. Thyroiditis can present with or without endocrinopathy.

Hormones 52

Hormones Trials Genome Genomics 52

The Pharma Data

AUGUST 11, 2020

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. Institute hormone replacement therapy for endocrinopathies as warranted.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52